Close Menu

This story has been updated to include comments from a conference call with investors.

NEW YORK – Meridian Bioscience reported on Friday that its fiscal fourth quarter revenues increased 26 percent year over year, with reagent sales more than offsetting a dip in diagnostics revenues.

For the three months ended Sept. 30, the firm reported revenues of $64.2 million up from $50.8 million a year ago and beating the average consensus Wall Street estimate of $59.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.